Piper Sandler downgrades Globe Life to Neutral and cuts price target to $165
Piper Sandler lowered its rating on Globe Life to Neutral from Overweight and reduced its price target from $200 to $165, citing higher medical claim severity, irregular Medicare supplement claims and weaker 2027 guidance. The downgrade followed Globe Life’s third‑quarter 2026 results, where revenue rose to $1.6 billion but net operating income per share fell to $4.84, missing estimates. Analysts noted that the stock fell sharply after the downgrade.
Why it matters
Piper Sandler’s downgrade signals to investors that earnings volatility may increase, which could pressure Globe Life’s share price and reduce upside expectations. The analyst’s new $165 target suggests a lower valuation ceiling for the stock.
Key facts
- 1Piper Sandler changed its rating on Globe Life to Neutral from Overweight. investing.com
- 2The firm cut its price target to $165 from $200. investing.com
- 3Globe Life reported third‑quarter revenue of $1.6 billion, beating the $1.56 billion forecast. investing.com
- 4Third‑quarter net operating income per diluted share was $4.84, below the $4.91 estimate. investing.com
- 5Piper Sandler cited higher medical‑claim severity, irregular Medicare supplement claims and weaker 2027 guidance as the reasons for the downgrade. finance.yahoo.com
Open questions
- Material 2 reports a 3.4% pre‑market decline, while material 4 reports an 8% drop after the downgrade.
Summary written by AlphAI AI Desk from 4 of 4 sources. Not investment advice. Figures are as stated by the linked sources.